Thomas Ischinger

5.8k total citations · 1 hit paper
61 papers, 3.2k citations indexed

About

Thomas Ischinger is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Ischinger has authored 61 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Surgery, 28 papers in Cardiology and Cardiovascular Medicine and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Ischinger's work include Coronary Interventions and Diagnostics (38 papers), Cerebrovascular and Carotid Artery Diseases (21 papers) and Cardiac Imaging and Diagnostics (17 papers). Thomas Ischinger is often cited by papers focused on Coronary Interventions and Diagnostics (38 papers), Cerebrovascular and Carotid Artery Diseases (21 papers) and Cardiac Imaging and Diagnostics (17 papers). Thomas Ischinger collaborates with scholars based in Germany, United States and Netherlands. Thomas Ischinger's co-authors include Bernhard Meier, Andreas R. Gruentzig, Spencer B. King, Jay Hollman, John S. Douglas, Christian W. Hamm, Jacobus Reimers, Hans‐Jürgen Rupprecht, Stephan Windecker and Carlo Di Mario and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Thomas Ischinger

61 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

2008 453 citations Stephan Windecker, Patrick W. Serruys et al. The Lancet profile →

Peers

Countries citing papers authored by Thomas Ischinger

Since Specialization

Citations

This map shows the geographic impact of Thomas Ischinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Ischinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Ischinger more than expected).

Fields of papers citing papers by Thomas Ischinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Ischinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Ischinger. The network helps show where Thomas Ischinger may publish in the future.

Co-authorship network of co-authors of Thomas Ischinger

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Ischinger. A scholar is included among the top collaborators of Thomas Ischinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Ischinger. Thomas Ischinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TCT-569 5-year Clinical Outcomes of Biodegradable Polymer Biolimus-eluting Stents versus Durable Polymer Sirolimus-eluting Stents in Patients with and without Diabetes Mellitus: a LEADERS Sub-study 2012 ·Journal of the American College of Cardiology ·Axel Linke, Paweł Buszman, Patrick W. Serruys, Thomas Ischinger, Diethmar Antoni, Volker Klauß, Hae‐Young Sohn, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Peter Jüni, Stephan Windecker	1
2	TCT-44 LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study 2012 ·Journal of the American College of Cardiology ·Patrick W. Serruys, Paweł Buszman, Axel Linke, Thomas Ischinger, Diethmar Antoni, Volker Klauß, Hae‐Young Sohn, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Peter Jüni, Stephan Windecker	11
3	Aortic valve calcium score as a predictor for outcome after TAVI using the CoreValve revalving system 2011 ·International Journal of Cardiology ·Alexander Leber, Markus Kasel, Thomas Ischinger, (unknown), Diethmar Antoni, Martin Schmidt, (unknown), (unknown), Armin Huber, Thomas Helmberger, Ellen Hoffmann	70
4	The three year follow-up of the randomised “all-comers” trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS) 2011 ·EuroIntervention ·Joanna J. Wykrzykowska, Patrick W. Serruys, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Gerrit-Anne van Es, Peter Jüni, Stephan Windecker	36
5	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice 2011 ·JACC: Cardiovascular Interventions ·Volker Klauß, Patrick W. Serruys, Thomas Pilgrim, Paweł Buszman, Axel Linke, Thomas Ischinger, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Gerrit‐Anne van Es, Bindu Kalesan, Peter Wenaweser, Peter Jüni, Stephan Windecker	26
6	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial 2011 ·The Lancet ·Giulio Stefanini, Bindu Kalesan, Patrick W. Serruys, Dik Heg, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Franz R. Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Roberto Corti, Diethmar Antoni, Hae Young Sohn, Pedro Eerdmans, Gerrit‐Anne van Es, Bernhard Meier, Stephan Windecker, Peter Jüni	245
7	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial 2011 ·EuroIntervention ·Joanna J. Wykrzykowska, Scot Garg, Yoshinobu Onuma, Ton de Vries, Marie-Angèle Morel, Gerrit-Anne van Es, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Roberto Corti, Franz R. Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Peter Jüni, Stephan Windecker, Patrick W. Serruys	19
8	VALUE OF THE SYNTAX SCORE (SX) FOR RISK ASSESSMENT IN THE “ALL-COMERS” POPULATION OF THE RANDOMIZED MULTICENTER LEADERS TRIAL. 2010 ·Journal of the American College of Cardiology ·Joanna J. Wykrzykowska, Scot Garg, (unknown), Ton de Vries, Marie‐Angèle Morel, Gerrit‐Anne van Es, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Roberto Corti, Franz Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Peter Jüni, Stephan Windecker, Patrick W. Serruys	10
9	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer 2009 ·JACC: Cardiovascular Interventions ·Joanna J. Wykrzykowska, Patrick W. Serruys, Yoshinobu Onuma, Ton de Vries, Gerrit-Anne van Es, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Roberto Corti, Franz R. Eberli, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Robert‐Jan van Geuns, Peter Jüni, Stephan Windecker	39
10	Effectiveness and Safety of Carotid Artery Stenting for Significant Carotid Stenosis in Patients With Contralateral Occlusion (from the German ALKK-CAS Registry Experience) 2009 ·The American Journal of Cardiology ·Rajendra H. Mehta, Ralf Zahn, Matthias Hochadel, Harald Mudra, Thomas Ischinger, Karl-Eugen Hauptmann, Jens Jung, Hubert Seggewiß, Uwe Zeymer, Jochen Senges	17
11	Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy 2009 ·EuroIntervention ·Joanna J. Wykrzykowska, Lorenz Räber, Ton de Vries, Marco Bressers, Paweł Buszman, Axel Linke, Thomas Ischinger, Volker Klauß, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Evelyn Regar, Peter Jüni, Stephan Windecker, (unknown)	7
12	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial breakdown → 2008 ·The Lancet ·Stephan Windecker, Patrick W. Serruys, Simon Wandel, Paweł Buszman, (unknown), Axel Linke, Karsten Lenk, Thomas Ischinger, Volker Klauß, Franz R. Eberli, Roberto Corti, William Wijns, Marie‐Claude Morice, Carlo Di Mario, Simon Davies, Robert‐Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Peter Jüni	453
13	13-year follow-up of the German angioplasty bypass surgery investigation 2005 ·European Heart Journal ·Jan Kaehler, Ralf Koester, (unknown), Christian Schroeder, Hans‐Jürgen Rupprecht, Thomas Ischinger, Roland Jahns, Albrecht Vogt, (unknown), Rainer Hoffmann, Reimer Rießen, Joachim Berger, Thomas Meinertz, Christian W. Hamm	20
14	Angiographic outcome after intracoronary X‐Sizer helical atherectomy and thrombectomy: First use in humans 2002 ·Catheterization and Cardiovascular Interventions ·(unknown), Ross Prpic, Jorge Gaspar, Detlef G. Mathey, A Escobar, (unknown), Nicolaus Reifart, Thomas Ischinger, Jeffrey J. Popma	15
15	Angiographic follow-up results of a randomized study on angioplasty versus bypass surgery (GABI Trial) 1996 ·European Heart Journal ·H.-J. Rupprecht, Christian W. Hamm, Thomas Ischinger, Ulrich A. Dietz, Jacobus Reimers, J. Meyer, (unknown)	25
16	Clinical outcome and costs of CABG and PTCA in the GABI study over 2 years follow-up 1996 ·Journal of the American College of Cardiology ·Christian W. Hamm, P. Kalmár, Jacobus Reimers, Hans‐Jürgen Rupprecht, C. G. Schmidt, Thomas Ischinger	4
17	A Randomized Study of Coronary Angioplasty Compared with Bypass Surgery in Patients with Symptomatic Multivessel Coronary Disease 1994 ·New England Journal of Medicine ·Christian W. Hamm, Jacobus Reimers, Thomas Ischinger, Hans‐Jürgen Rupprecht, Jürgen Berger, W. Bleifeld	359
18	Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: Implications for photodynamic therapy of vascular stenoses 1990 ·Journal of the American College of Cardiology ·Peter C. Dartsch, Thomas Ischinger, E. Betz	44
19	Immediate and short-term benefit of multilesion coronary angioplasty: Influence of degree of revascularization 1985 ·Journal of the American College of Cardiology ·Michel Vandormael, (unknown), Thomas Ischinger, Ümit T. Aker, Michael Harper, (unknown), Ubeydullah Deligönül, Harold L. Kennedy	120
20	Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery 1983 ·Journal of the American College of Cardiology ·John S. Douglas, Andreas R. Gruentzig, Spencer B. King, Jay Hollman, Thomas Ischinger, Bernhard Meier, Joseph M. Craver, Ellis L. Jones, John L. Waller, David Bone, Robert A. Guyton	174

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact